Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Vinflunine||Javlor||Javlor (vinflunine) is a third-generation vinca alkaloid that disrupts microtubule function which leads to tumor cell death (PMID: 19337431).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||breast cancer||not applicable||Vinflunine||Phase III||Actionable||In a Phase III trial, Javlor (vinflunine) treatment did not improve overall survival (9.1 vs 9.3 months, HR=1.04, p=0.67) compared to physician's choice of alkylating agent in patients with metastatic breast cancer (PMID: 29481630; NCT01091168).||29481630|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03410693||Phase II||Docetaxel Vinflunine Paclitaxel Rogaratinib||Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma (FORT-1)||Active, not recruiting|